Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2002)
7 slides from Genetic Technologies's shareholder meeting presentation, Nov 29, 2002
Slide 1: Presentation by Dr. Mervyn Jacobson, Executive Chairman
Presentation by Dr. Mervyn Jacobson, Executive Chairman to the Annual General Meeting of Genetic Technologies Limited (“GTG”) Melbourne, November 29th, 2002 Introductory Comments Ladies and Gentlemen - good morning — | have previously presented and summarised the background events which led to Genet
Slide 2: (1) Expanding our Service Testing Business
(1) Expanding our Service Testing Business — (a) Paternity Testing - GTG already owns and operates the largest accredited DNA testing lab in Australia for paternity testing — and last year we further expanded that business by acquiring the small Perth-based laboratory, “DNA-ID Labs”. Overall, the GT
Slide 3: (2) Generating Significant Licensing Revenues
(2) Generating Significant Licensing Revenues — Last year, | explained we believed GTG had a significant opportunity to out-license the original GeneType patents to other leading biotechnology companies world-wide - in return for substantial revenues for GTG. Such revenues for GTG could take the for
Slide 4: Likely scope or total potential of our licensing programme
We are continually being asked what is the likely scope or total potential of our licensing programme. The short answer seems to be — it is possibly very substantial. More and more articles in scientific journals are now confirming the relevance of the non-coding DNA, and we believe there are today
Slide 5: (4) The PGGP Program
(4) The PGGP Program — GTG’s Pathogen Genomics and Genetics Program ("PGGP’) is a collaboration with the Department of Veterinary Science at Melbourne University, under the supervision of Professor Robin Gasser, with GTG as the industry partner. The object is to look for novel, gene-based approaches
Slide 6: (7) Pursuing the U.S. Connection
(7) Pursuing the U.S. Connection. GTG continues to build its presence in North America, in several ways: (i) Licensing the GeneType patents in USA ~ this effort continues to expand, with the support of our Denver-based intellectual property attorneys and licensing attorneys. (ii) Pursuing a NASDAQ L
Slide 7: In conclusion
In conclusion: Despite the generally difficult trading conditions of the last year, your Board is pleased to report steady and positive progress by GTG in relation to our general growth, revenues, scientific research and financial condition. In summary, we note: pleasing growth in service testing re
Genetic Technologies — Shareholder Meeting (November 2002) on 6ix